Sep 2026
Hypoxia-activated 2-nitroimidazole-brusatol carbonate prodrugs for enhanced gastric cancer therapy with reduced systemic toxicity.
This work describes the first hypoxia-activated BST prodrug with potent in vivo efficacy and improved safety, providing a targeted delivery strategy and a promising lead agent for gastric cancer treatment.
Ji-Chong Li, Xue-Lan Ma, Zi-Jian Liu et al.
· Bioorganic & Medicinal Chemi... · 0 citations